@article{oai:repo.qst.go.jp:00084787,
 author = {Saito, Takashi and Ohnishi, Kayoko and Ishikawa, Hitoshi and Nakamura, Masatoshi and Hoshiai, Sodai and Numajiri, Haruko and Nemoto Murofushi, Keiko and Mizumoto, Masashi and Okumura, Toshiyuki and Sakurai, Hideyuki and Hitoshi, Ishikawa and Hideyuki, Sakurai},
 issue = {11},
 journal = {Anticancer research},
 month = {Nov},
 note = {Background/Aim: To evaluate the outcomes of proton beam therapy (PBT) for early-stage non-small cell lung cancer (NSCLC) in patients with interstitial lung disease (ILD). Patients and Methods: Between 2002 and 2017, 110 patients receiving hypofractionated PBT for cT1-2N0M0 NSCLC were reviewed.
Results: Of the 110 patients, 17 were diagnosed with ILD. The median follow-up period was 37.8 months. No significant difference in the 1-year cumulative rate of grade ≥2 pneumonitis was observed between patients with and those without ILD (17.6% vs. 14.1%, p=0.708). The lung doses were significantly lower in patients with than in those without ILD among patients without grade ≥2  neumonitis. There were no significant differences in overall survival or local recurrence-free rates according to the presence of ILD. Conclusion: PBT appears to be a feasible and effective treatment for cT1-2N0M0 NSCLC in
patients with ILD, but the lung dose should be strictly reduced.},
 pages = {5635--5642},
 title = {Hypofractionated Proton Beam Therapy for cT1-2N0M0 Non-small Cell Lung Cancer Patients With Interstitial Lung Disease},
 volume = {41},
 year = {2021}
}